Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 14, 2021

Primary Completion Date

August 27, 2021

Study Completion Date

August 27, 2021

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Monomethyl Fumarate 190 Mg

2 x oral 95 mg capsules, delayed-release

DRUG

Diroximel Fumarate 462 mg

2 x 231 mg capsules, delayed-release

Trial Locations (1)

BioPharma Services, Inc., St Louis